報價延遲最少15分鐘:2024/05/05 16:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1513 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.22/-0.70
|
|
企業價值
6.14M
|
| 資產負債 |
|
每股賬面淨值
-0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/05 16:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America. |